Off-label antidepressant use in children and adolescents compared with young adults: extent and level of evidence

Authors

  • Angela S. Czaja,

    Corresponding author
    1. Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA
    • Children's Hospital Colorado, Aurora, CO, USA
    Search for more papers by this author
  • Robert Valuck

    1. Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA
    Search for more papers by this author

  • A portion of this work was presented at the 27th annual International Conference on Pharmacoepidemiology and Therapeutic Risk Management, August 2011, Chicago, USA.

A. S. Czaja, Pediatric Critical Care, University of Colorado, MS 8414, 13121 E. 17th Ave, Aurora, CO 80045, USA. E-mail: angela.czaja@childrenscolorado.org

ABSTRACT

Purpose

To estimate the degree of, and level of evidence supporting, off-label antidepressant (AD) prescribing for children and adolescents compared with young adults.

Methods

Retrospective cohort study utilizing medical and pharmacy claims data from US-managed care plans, 1997–2009.

Participants

Patients aged 5–24 years, with at least one (index) AD claim during a period of continuous enrollment.

Main outcome measures

Drug-diagnosis pairs, on the basis of medical claims within 30 days pre-index or post-index AD, were grouped as (1) Food and Drug Administration (FDA)-approved or (2) off-label with one of three evidence categories based on Micromedex®2.0: favorable, inconclusive or limited-to-none (Thomson Micromedex, Greenwood Village, CO, USA).

Results

Over the study period, 290 816 subjects met eligibility criteria: 17% 5–12 years old, 40% 13–18 years old, and 43% 19–24 years old. Sertraline was the most commonly prescribed index AD (19–23%). Psychiatrists more often prescribed the AD for children (31%) and adolescents (35%) versus young adults (17%). Only 28% of all subjects had a diagnosis consistent with an FDA-approved indication within 30 days pre-index and post-index AD. Children less than 13 years old were less likely to have had an FDA-approved indication (5–10%). Most off-label prescribing had inconclusive to no evidence supporting efficacy. The lack of evidence was especially pronounced for younger children. Trends were consistent over the study period. Increasing the time period for potential indications pre-index and post-index AD did not result in significantly reduced off-label rates.

Conclusions

Pediatric off-label AD prescribing occurs frequently without a strong evidence base, highlighting a need to generate additional evidence to ensure safe and effective use. Copyright © 2012 John Wiley & Sons, Ltd.

Ancillary